{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"Number of participants that have achieved Complete response (CR). Complete response definition is negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates.","groups":[{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"OG000","title":"Group1_Dose 1 200mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"OG001","title":"Group 1_Dose 2 225mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"OG002","title":"Group 2_Dose 1 200mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"OG003","title":"Group 2_Dose 225mgm2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 90 days post-transplant","title":"Number of Participants That Have Achieved Complete Response (CR).","type":"SECONDARY","unitOfMeasure":"Participants"}